Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Le Tourneau

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 30, 2019
[Boost in proton for locally advanced nasopharyngeal carcinoma: A Curie Institute experience]A Beddok, L Feuvret, G Noël, et al.
La Revue De Medecine Interne|February 15, 2008
[Cholangiocarcinoma: epidemiology and global management]C Dreyer, C Le Tourneau, S Faivre, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaE Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 21, 2019
Medical Oncology Workload in Europe: One Continent, Several WorldsB Seruga, R Sullivan, A Fundytus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancerC Massard, A Azaro, J-C Soria, et al.
NPJ Precision Oncology|July 21, 2021
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
NPJ Precision Oncology|September 18, 2021
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine GlossaryL R Yates, J Seoane, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approachR Galot, C Le Tourneau, J Guigay, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 30, 2019
[Boost in proton for locally advanced nasopharyngeal carcinoma: A Curie Institute experience]A Beddok, L Feuvret, G Noël, et al.
La Revue De Medecine Interne|February 15, 2008
[Cholangiocarcinoma: epidemiology and global management]C Dreyer, C Le Tourneau, S Faivre, et al.
Investigational New Drugs|April 7, 2019
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinomaC Even, U Lassen, J Merchan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaE Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 21, 2019
Medical Oncology Workload in Europe: One Continent, Several WorldsB Seruga, R Sullivan, A Fundytus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2018
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancerC Massard, A Azaro, J-C Soria, et al.
NPJ Precision Oncology|July 21, 2021
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
NPJ Precision Oncology|September 18, 2021
Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world populationC B Westphalen, M G Krebs, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine GlossaryL R Yates, J Seoane, C Le Tourneau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approachR Galot, C Le Tourneau, J Guigay, et al.
Pageof 6